528 Editorials| JNCI Vol. 103, Issue 7| April 6, 2011 the many pieces of efficacy data that
have emerged in the time since the very first phase I IM trial was published (3). The …

Imatinib therapy for chronic myeloid leukemia: where do we go now? - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

We investigated whether increasing the dose of imatinib mesylate might overcome drug
resistance in patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous …

Purpose: Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL
fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia …

Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid
leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have …

Imatinib (IM) is the current first line treatment for chronic myeloid leukemia (CML). However,
the disease will progress in the majority of patients pausing IM. IFN-α may intensify the …

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia
patients at 3-year follow-up. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

In this article, the authors briefly recap the key clinical trials that involve imatinib mesylate
(Gleevec, Glivec, STI571). Because the reader may be familiar with many of these …

Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …